KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, announced today that the first twenty-five percent (20 of 80) of melanoma subjects have been treated in Provectus Pharmaceuticals’ Phase 2 clinical trial of PV-10. Additional subjects are being evaluated for eligibility for entrance into the trial or are awaiting treatment at the two active centers in Brisbane and Sydney, Australia. In addition, Provectus anticipates opening the first United States site for the trial in the very near future. Currently, Provectus is also sponsoring Phase 2 trials for psoriasis and atopic dermatitis in New York and Florida.
